EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Matinas BioPharma Holdings's enterprise value is $33.67 Mil.
Matinas BioPharma Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.10 Mil. Therefore, Matinas BioPharma Holdings's EV-to-Revenue for today is 30.72.
The historical rank and industry rank for Matinas BioPharma Holdings's EV-to-Revenue or its related term are showing as below:
MTNB'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.98 Med: 811.76 Max: 3802.95
Current: 30.72
During the past 11 years, the highest EV-to-Revenue of Matinas BioPharma Holdings was 3802.95. The lowest was 2.98. And the median was 811.76.
MTNB's EV-to-Revenue is ranked worse than 72.88% of 1036
companies
in the Biotechnology industry
Industry Median: 8.285
vs MTNB: 30.72
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Matinas BioPharma Holdings's EV-to-Revenue
For the Biotechnology subindustry, Matinas BioPharma Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Matinas BioPharma Holdings's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Matinas BioPharma Holdings's EV-to-Revenue falls into.
Matinas BioPharma Holdings's current Enterprise Value is $33.67 Mil.
Matinas BioPharma Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Matinas BioPharma Holdings's share price for today is $0.1756.
Matinas BioPharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Matinas BioPharma Holdings EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Matinas BioPharma Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Matinas BioPharma Holdings (Matinas BioPharma Holdings) Business Description
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MTNB has been successfully added to your 